Roth Capital Equities Analysts Reduce Earnings Estimates for Accuray Incorporated (NASDAQ:ARAY)

Accuray Incorporated (NASDAQ:ARAY) – Equities research analysts at Roth Capital dropped their Q4 2024 earnings per share (EPS) estimates for Accuray in a research note issued on Thursday, May 2nd. Roth Capital analyst J. Wittes now anticipates that the medical equipment provider will post earnings of $0.04 per share for the quarter, down from their prior estimate of $0.05. Roth Capital currently has a “Buy” rating on the stock. The consensus estimate for Accuray’s current full-year earnings is ($0.07) per share. Roth Capital also issued estimates for Accuray’s FY2026 earnings at $0.13 EPS.

Several other equities analysts have also recently issued reports on ARAY. Roth Mkm initiated coverage on Accuray in a research report on Tuesday, February 13th. They set a “buy” rating and a $9.00 target price on the stock. TheStreet lowered Accuray from a “c-” rating to a “d+” rating in a research note on Wednesday, February 14th. One analyst has rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Accuray presently has a consensus rating of “Moderate Buy” and an average price target of $8.25.

Accuray Stock Performance

Shares of ARAY stock opened at $1.62 on Friday. The stock has a market capitalization of $160.66 million, a PE ratio of -7.36 and a beta of 1.48. Accuray has a 52-week low of $1.51 and a 52-week high of $4.30. The stock’s 50-day moving average price is $2.41 and its 200 day moving average price is $2.61. The company has a quick ratio of 0.84, a current ratio of 1.58 and a debt-to-equity ratio of 3.53.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings results on Wednesday, May 1st. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.05). The company had revenue of $101.13 million during the quarter, compared to analyst estimates of $114.60 million. Accuray had a negative net margin of 4.99% and a negative return on equity of 42.34%. During the same quarter last year, the firm earned $0.01 EPS.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ARAY. Silverberg Bernstein Capital Management LLC acquired a new position in Accuray in the 4th quarter valued at $1,194,000. First Eagle Investment Management LLC increased its holdings in shares of Accuray by 44.3% during the 3rd quarter. First Eagle Investment Management LLC now owns 910,925 shares of the medical equipment provider’s stock worth $2,478,000 after buying an additional 279,478 shares during the last quarter. Heartland Advisors Inc. increased its holdings in shares of Accuray by 6.8% during the 3rd quarter. Heartland Advisors Inc. now owns 2,847,800 shares of the medical equipment provider’s stock worth $7,746,000 after buying an additional 181,050 shares during the last quarter. North Star Investment Management Corp. increased its holdings in Accuray by 16.8% in the 4th quarter. North Star Investment Management Corp. now owns 1,095,920 shares of the medical equipment provider’s stock valued at $3,101,000 after purchasing an additional 157,975 shares in the last quarter. Finally, Acuitas Investments LLC increased its holdings in Accuray by 14.7% in the 4th quarter. Acuitas Investments LLC now owns 708,553 shares of the medical equipment provider’s stock valued at $2,005,000 after purchasing an additional 91,053 shares in the last quarter. 64.08% of the stock is currently owned by institutional investors and hedge funds.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.